SCHEMBL6311544

SCHEMBL6311544

COc1cc(Nc2ncc(-c3ccccn3)c(N)n2)cc(OC)c1OC

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 5/20 0.66
KDR P35968 4/20 0.57
AURKA O14965 1/20 0.57
AURKB Q96GD4 1/20 0.57
IGF1R P08069 6/20 0.56
AXL P30530 1/20 0.54
JAK2 O60674 2/20 0.54
JAK1 P23458 1/20 0.54
TYK2 P29597 1/20 0.54
JAK3 P52333 1/20 0.54
ULK1 O75385 1/20 0.53
PRKD3 O94806 1/20 0.52
PRKCG P05129 1/20 0.52
PRKCB P05771 1/20 0.52
LCK P06239 1/20 0.52
PRKCA P17252 1/20 0.52
PRKCH P24723 1/20 0.52
PRKCI P41743 1/20 0.52
ZAP70 P43403 1/20 0.52
PRKCE Q02156 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17940843 0.90 PTK2 (0.57) PTK2KDRAURKAAURKBIGF1R
SCHEMBL17940841 0.87 TGFBR1 (0.55) PTK2KDRAURKAAURKBIGF1R
SCHEMBL6312565 0.85 IGF1R (0.57) PTK2KDRAURKAAURKBIGF1R
SCHEMBL6311515 0.82 KDR (0.52) PTK2KDRAURKAAURKBIGF1R
SCHEMBL6312589 0.80 IGF1R (0.59) PTK2KDRAURKAAURKBIGF1R
SCHEMBL6980729 0.80 IGF1R (0.68) PTK2KDRAURKAAURKBIGF1R
SCHEMBL14635173 0.79 AXL (0.62) PTK2KDRAURKAAURKBIGF1R
SCHEMBL2205447 0.79 IGF1R (0.63) PTK2KDRAURKAAURKBIGF1R
SCHEMBL6317955 0.78 IGF1R (0.57) PTK2KDRAURKAAURKBIGF1R
SCHEMBL27997729 0.78 FYN (0.59) PTK2KDRAURKAAURKBIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939874-B2 Substituted pyrimidinyl derivatives and methods of use AMGEN INC. (US) 2005-09-06 US disclosed
EP-1427421-A1 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS Amgen Inc. (US) 2004-06-16 EP disclosed
US-20040063705-A1 Substituted pyrimidinyl derivatives and methods of use AMGEN INC. 2004-04-01 US disclosed
WO-2003018021-A1 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS AMGEN INC. (US) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063705-A1 Substituted pyrimidinyl derivatives and methods of use DPYD, TYMP, TPMT PTK2 3457/4885KDR 2148/4885AURKA 2306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.